1. Home
  2. Additional clinical information

Risk stratification for survival in metastatic renal cell carcinoma

This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document. 

Prognostic factors and risk stratification for survival in patients with metastatic renal cell carcinoma (RCC).

The two most commonly utilised prognostic scoring systems for defining risk groups in patients with metastatic RCC are the Memorial Sloan Kettering Cancer Center (MSKCC) modelr,r and the International Metastatic RCC Database Consortium (IMDC) model,r,r colloquially known as the 'Motzer' and 'Heng' score respectively. The models separate patients into three distinct risk groups (favourable/intermediate/poor) with varying survival rates.

Note: The model does not address differences in histology.

MSKCCr
prognostic factors

IMDCr
prognostic factors
Karnofsky performance score Less than 80% Karnofsky performance score Less than 80%
Time from diagnosis to systemic treatment Less than 12 months Time from diagnosis to systemic treatment Less than 12 months
Haemoglobin Less than lower limit of laboratory reference range Haemoglobin Less than lower limit of laboratory reference range
Corrected serum calcium Greater than 2.5 mmol/L Corrected serum calcium Greater than upper limit of laboratory reference range
Lactate dehydrogenase Greater than 1.5 times the upper limit of laboratory reference range Neutrophils Greater than upper limit of laboratory reference range
    Platelets Greater than upper limit of laboratory reference range

Median overall survival

MSKCC risk group

Prognostic factors

Median overall survivalr (months)
Favourable 0 29.6
Intermediate 1 or 2 13.8
Poor 3 or more 4.9

IMDC risk group

Prognostic factors

Median overall survivalr (months)
Favourable 0 43.2
Intermediate 1 or 2 22.5
Poor 3 or more 7.8
On this page
Expand all Collapse all Back to top
[%id%]
[%title%]
[%abstract%]

Version 3

Date Summary of changes
31/05/2017

Transferred to new eviQ website. Version number change to V.2.

Previous website ID: 215
04/04/2019 Document reviewed by Medical Oncology Reference Committee. CCF model replaced with IMDC model. Version number change to V.3. Next review in 2 years.

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3053

20 Apr 2024